At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Efficacy of Wound Dressing Containing Silk Sericin for Split-thickness Skin Graft Donor Site Treatment
In Brief
A Phase 2 clinical trial evaluating Sericin scaffold for Late Complication From Skin Graft and 3 related conditions. Completed, enrolled 30 participants across 1 site.
Detailed Summary
1. Silk sericin wound dressing may reduce time for complete epithelialisation of split-thickness skin graft donor sites compared to Bactigras®. 2. Silk sericin wound dressing may reduce pain level at split-thickness skin graft donor sites compared to Bactigras® . 3. Silk sericin wound dressing may not cause split-thickness skin graft donor sites infection as compared to Bactigras®. 4. Split-thickness skin graft donor sites which treat by silk sericin wound dressing may not cause significant adverse events.
Study Details
Timeline
Interventions
Device: wound dressing containing silk sericin A scaffold from silk sericin-polyvinyl alcohol-glycerin blending are applied on one half of the skin graft donor site Device: fine mesh gauze impregnated with paraffin and 0.5%chlorhexidine acetate (Bactigras, Smith\&Nephew, London, UK) are applied on the other half of the skin graft donor site